Virbac targets upper end of 5.5%-7.5% 2026 revenue growth range at CERS, sees recurring operating margin around 17%

• Virbac kept 2026 guidance, targeting the upper end of 5.5%-7.5% revenue growth at constant exchange rates and scope.
• Adjusted recurring operating income margin still expected at around 17% at constant exchange rates and scope.
• Guidance follows H1 revenue of EUR 768 million, up 7.4% at constant exchange rates and scope, up 4% at actual rates.
• Cash generation outlook unchanged at about EUR 80 million, including capex of around EUR 125 million.
• Thyronorm expected to add about 1 percentage point to full-year revenue growth, about 0.5 adjusted EBIT.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virbac SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607201145OMX_____CNEWS_EN_GNW1001213571_en) on July 20, 2026, and is solely responsible for the information contained therein.